据业内多方消息,何如意或将加入扬子江药业,暂任首席医学官(CMO)一职。但截至目前,此消息尚未获得双方的正面回应。据悉,杨子江方面曾明确表示,要攻克创新药领域,并将创新作为核心战略,重点布局抗肿瘤、神经系统、内分泌、心血管等领域的创新药研发,建立1500余人的研发团队,推进化药、中药、生物药“三药并举”。在2024年的年终工作报告中,扬子江还曾提到,要通过研发创新驱动,加大投入,加强协作,加快落地...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.